A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Chronic Pruritus of Unknown Origin
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Stapokibart (Primary) ; Mometasone
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors KeyMed Biosciences
Most Recent Events
- 12 Jul 2022 New trial record